146 related articles for article (PubMed ID: 1411635)
1. Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives.
Clark PI
Semin Oncol; 1992 Apr; 19(2 Suppl 6):20-7. PubMed ID: 1411635
[TBL] [Abstract][Full Text] [Related]
2. The clinical pharmacology of etoposide and teniposide.
Clark PI; Slevin ML
Clin Pharmacokinet; 1987 Apr; 12(4):223-52. PubMed ID: 3297462
[TBL] [Abstract][Full Text] [Related]
3. The clinical pharmacology of etoposide.
Slevin ML
Cancer; 1991 Jan; 67(1 Suppl):319-29. PubMed ID: 1984835
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic optimisation of treatment with oral etoposide.
Toffoli G; Corona G; Basso B; Boiocchi M
Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16).
Long BH
Semin Oncol; 1992 Apr; 19(2 Suppl 6):3-19. PubMed ID: 1329225
[TBL] [Abstract][Full Text] [Related]
6. Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide.
Stewart DJ; Grewaal D; Redmond MD; Mikhael NZ; Montpetit VA; Goel R; Green RM
Cancer Chemother Pharmacol; 1993; 32(5):368-72. PubMed ID: 8339387
[TBL] [Abstract][Full Text] [Related]
7. Schedule-dependent topoisomerase II-inhibiting drugs.
Joel SP; Slevin ML
Cancer Chemother Pharmacol; 1994; 34 Suppl():S84-8. PubMed ID: 8070033
[TBL] [Abstract][Full Text] [Related]
8. Absolute bioavailability and pharmacokinetics of oral teniposide.
Splinter TA; Holthuis JJ; Kok TC; Post MH
Semin Oncol; 1992 Apr; 19(2 Suppl 6):28-34. PubMed ID: 1411636
[TBL] [Abstract][Full Text] [Related]
9. The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.
Roed H; Vindelov LL; Christensen IJ; Spang-Thomsen M; Hansen HH
Cancer Chemother Pharmacol; 1987; 19(1):16-20. PubMed ID: 3815721
[TBL] [Abstract][Full Text] [Related]
10. The pharmacology of intravenous and oral etoposide.
Carney DN
Cancer; 1991 Jan; 67(1 Suppl):299-302. PubMed ID: 1984831
[TBL] [Abstract][Full Text] [Related]
11. [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Moritaka T; Tabata M; Segawa Y; Shibayama T; Gemba K; Matsumura T
Gan To Kagaku Ryoho; 1993 Mar; 20(4):473-7. PubMed ID: 8383949
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion.
Montaldo PG; Figoli F; Zanette ML; Sorio R; Zucchetti M; Tirelli U; D'Incalci M
Oncology; 1990; 47(1):55-61. PubMed ID: 2300386
[TBL] [Abstract][Full Text] [Related]
13. Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.
Holthuis JJ
Pharm Weekbl Sci; 1988 Jun; 10(3):101-16. PubMed ID: 3047665
[TBL] [Abstract][Full Text] [Related]
14. Podophyllotoxin derivatives VP-16 and VM-26.
D'Incalci M; Garattini S
Cancer Chemother Biol Response Modif; 1988; 10():57-63. PubMed ID: 3079398
[No Abstract] [Full Text] [Related]
15. Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?
Allen LM; Tejada F; Okonmah AD; Nordqvist S
Cancer Chemother Pharmacol; 1982; 7(2-3):151-6. PubMed ID: 7083456
[TBL] [Abstract][Full Text] [Related]
16. Podophyllotoxin derivatives.
D'Incalci M; Garattini S
Cancer Chemother Biol Response Modif; 1992; 13():75-82. PubMed ID: 1389926
[No Abstract] [Full Text] [Related]
17. The podophyllotoxin derivatives VP16-213 and VM26.
Issell BF
Cancer Chemother Pharmacol; 1982; 7(2-3):73-80. PubMed ID: 7044593
[TBL] [Abstract][Full Text] [Related]
18. A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007.
Xu H; Lv M; Tian X
Curr Med Chem; 2009; 16(3):327-49. PubMed ID: 19149581
[TBL] [Abstract][Full Text] [Related]
19. The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review.
Nissen NI; Dombernowsky P; Hansen HH; Pedersen AG
Recent Results Cancer Res; 1980; 74():98-106. PubMed ID: 7003663
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in semisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: an update (2008-2010).
Lv M; Xu H
Mini Rev Med Chem; 2011 Sep; 11(10):901-9. PubMed ID: 21781026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
